Its gene therapy is three years away from market, but Mustang is already thinking about outcomes-based pricing.
Pfizer opts not to start a price war with Alnylam and Ionis, but could there be a pricing loophole?
An Icer report questioning the cost effectiveness of Aimmune and DBV's peanut allergy projects is yet another reason to be cautious about the companies'…
The price in value-based payment deals should by definition be justified, so why is patient cost-sharing part of the calculation? Spark covers this cost, but there is no…
A price war over anti-PD-(L)1 drugs is raging in China, less than a year after the first one was approved. When could the US see something similar?
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Lilly's authorised Humalog generic price undercuts Sanofi’s copycat attack, but will cut into branded sales.
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.